ClinicalTrials.gg
CompletedNCT01284556Updated Nov 14, 2017

Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset Seizures

A Phase 3 interventional study of Phenobarbital and Placebo tablet in Epilepsy, sponsored by West-Ward Pharmaceutical. Completed at 4 sites in 2 countries. Open to participants aged 17 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-11-14.

Sponsored by West-Ward Pharmaceutical (part of Hikma Pharmaceuticals) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
314
Allocation
Randomized
Ages
17 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 793 studies in Epilepsy with a site in United States — 161 open to participants now, 194 under way, 17 of them phase 3. Epilepsy · United States.

Enrollment
56th of 588
314 · median 40
Started
2010
with 30 others
Phase 3
126 of 793
11 open now
Registered
226th of 793
by date

Among the 793 studies in Epilepsy with a site in United States, this one is the 56th largest by enrollment of the 588 interventional ones that give a count, is one of 31 that started in 2010, is one of 126 in phase 3, and was the 226th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

161 of the 793 studies in Epilepsy with a site in United States are open now. Recruiting first, the newest first:

156 more — sign in →

All 161 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 17 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 793 studies in Epilepsy with a site in United States, or all of them as a file.
02

Study summary

Primary:

  • to evaluate the efficacy of phenobarbital in reducing seizure frequency.

Secondary:

  • to confirm dose response relationship,
  • to assess the effects on Type I seizures,
  • to assess the safety of phenobarbital
  • to assess the drug tolerability.
Read the detailed description

Primary:

-to evaluate the efficacy of once daily (OD) administration of 60 mg and 100 mg phenobarbital, in reducing seizure frequency in participants with partial onset seizures (Type I seizures; complex or simple with motor symptoms only) not fully controlled despite treatment with 1 to 3 concomitant anti-epileptic drugs (AEDs) or AEDs with Vagus Nerve Stimulator (VNS)

Secondary:

  • to confirm dose response relationship of 60 and 100 mg phenobarbital doses,
  • to assess the effects of phenobarbital on Type I seizures,
  • to assess the safety of phenobarbital
  • to assess the tolerability of phenobarbital
03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • partial onset seizures
04

Who can participate

Ages eligible
17 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • participants from 17 to 70 years old;
  • history of Type I partial onset seizures (complex or simple with motor symptoms only);
  • participants must have had electroencephalogram (EEG), magnetic resonance imaging (MRI) or computed tomography (CT) with results consistent with diagnosis of partial-onset seizures;
  • participants having at least eight Type I partial onset seizures during 8-week baseline period;
  • participants being uncontrolled while treated by 1 to 3 permitted concomitant anti-epileptic drug (AED) and/or Vagus Nerve Stimulation (VNS);
  • participant has been on a stable dose of their current anti-epileptic treatment regime

Exclusion criteria

Exclusion Criteria:

  • currently taking phenobarbital or primidone;
  • currently taking felbamate or vigabatrin;
  • history of prior allergic reaction to phenobarbital;
  • history of psychogenic seizures;
  • history or presence of status epilepticus;
  • history or presence of seizures occurring only in clusters;
  • participant taking any drug with possible Central Nervous System (CNS) effects except if stable from 1 month prior Visit 1;
  • history of cerebrovascular accident (CVA) or (TIA);
  • presence of any sign suggesting rapidly progressing brain disorder or brain tumor;
  • presence of unstable arteriovenous malformations, meningiomas or other benign tumors;
  • history of porphyria;
  • presence of findings on physical exam, vital signs, (ECG) or safety lab assessments, including renal or hepatic insufficiency;
  • history of alcohol or drug abuse within the year prior to screening;
  • participant who is known to be non-compliant;
  • participant who is male or female who refuses to use an acceptable form of ;
  • female who is pregnant or lactating or intends to become pregnant;
  • participant who has taken part in any device or product within 2 months prior to the screening visit
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
314 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    placebo tablets

    Drug: Placebo tablet

  • Experimental
    60 mg group

    Patients titrated to 60mg phenobarbital for maintenance period, then titrated down.

    Drug: Phenobarbital

  • Experimental
    100 mg group

    Patients titrated to 100mg phenobarbital maintenance period, then titrated down

    Drug: Phenobarbital

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluate the efficacy of OD administration of 60 mg and 100 mg phenobarbital in reduction of seizure frequency

    * determination of partial onset seizure frequency per week over the treatment period * comparison of average change in weekly seizure rate from baseline and maintenance period

    Time frame: 34 weeks with maximum 22-week exposure to phenobarbital

Secondary outcomes

  1. Confirm the dose response relationship of 60 mg and 100 mg phenobarbital doses

    Time frame: 34 weeks with a maximum 22-week exposure to phenobarbital

  2. Assess the effects of phenobarbital on Type I seizures

    * seizure freedom rate * percent reduction for partial onset seizure * responder rate * reduction of seizure frequency

    Time frame: 34 weeks with a maximum 22-week exposure to phenobarbital

  3. Assess the safety of phenobarbital

    * overview of adverse events in study * summary of adverse events in study by severity, seriousness, relationship to study drug, action taken, outcome, treatment * summary of serious adverse events

    Time frame: 34 weeks with a maximum 22-week exposure to phenobarbital

  4. Assess the tolerability of phenobarbital

    Time frame: 34 weeks with maximum 22-week exposure to phenobarbital

07

Study locations

4 sites
  • Bluegrass Epilepsy Research
    Lexington, Kentucky 40504, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Centro Neurodiagnostico
    Rio Piedras, 00924, Puerto Rico
  • Hospital Del Maestro
    San Juan, 00927, Puerto Rico
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Jan 2013 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2011
First posted
Jan 27, 2011
Start
Nov 2010
Primary completionActual
Jan 2013
CompletionActual
Apr 2016
Last update
Nov 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01284556
Responsible party
Sponsor
First posted
Jan 27, 2011
Start date
Nov 2010
Primary completion
Jan 2013
Completion
Apr 2016
Last update
Nov 14, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Phenobarbital

Start the discussion